Peptide education
Melanotan-1
Melanotan I · MT-1 · Afamelanotide · NDP-alpha-MSH · Scenesse
Melanotan-1 is a name that points at two different things, and keeping them apart is most of the work. Chemically it is afamelanotide, also called NDP-alpha-MSH: a 13-amino-acid synthetic version of the pigment hormone alpha-MSH that activates the MC1 receptor and drives eumelanin production. As Scenesse, that molecule is an approved 16 mg implant for adults with erythropoietic protoporphyria. As a tanning-market vial or nasal spray, it is an unregulated product with no trials, no label, and no guarantee the contents match the name. The human evidence lives entirely on the implant side.
Behind the confusing name sits a real approved drug: Scenesse increased pain-free light exposure in randomized trials of adults with EPP, and a separate vitiligo trial found faster repigmentation when the implants were added to phototherapy. None of that evidence belongs to the vials and sprays sold to tanners under the Melanotan-1 name.
Overview
Quick answer
Melanotan-1, afamelanotide, and Scenesse are often mixed together in search results, but the product determines how far the evidence goes. A Scenesse implant is a regulated afamelanotide product for adults with EPP. A vial, nasal product, or tanning-market product labeled Melanotan-1 is not the same product, even when marketing uses afamelanotide evidence.
What is Melanotan-1?
Chemically, it is afamelanotide, also written NDP-alpha-MSH: a synthetic, superpotent version of the natural pigment hormone alpha-MSH. It switches on the MC1 receptor, which tells skin cells to make the dark pigment eumelanin. Online, the same name gets stuck on products that may contain anything.
What is it actually approved for?
Scenesse, a 16 mg afamelanotide implant, is approved to increase pain-free light exposure in adults with erythropoietic protoporphyria who have a history of phototoxic reactions. EPP is a disease where ordinary light can trigger severe skin pain, so extra time in daylight is a treatment outcome there, not a tan.
Why do people talk about tanning and photoprotection?
Because the mechanism is pigment biology: switch on MC1 and skin makes more eumelanin. The EPP trials were built on that, and the tanning market adopted the same logic for holidays, burn resistance, and cosmetic darkening. The studies never measured those goals, and the products sold for them are not Scenesse.
Has afamelanotide been studied in vitiligo?
Yes, with a positive result. In a 55-person randomized trial, everyone received NB-UVB phototherapy and 28 also received four monthly 16 mg afamelanotide implants; the combination repigmented faster and more completely, particularly in skin phototypes IV to VI. That is a real positive human signal for the implant added to phototherapy, not a current approved use and not evidence about Melanotan-1 vials or nasal products.
What routes and schedules are actually in the Scenesse label?
One 16 mg implant placed under the skin by a trained healthcare professional every 2 months. That is the whole labeled regimen. Nothing in the label or the trials supplies a self-injection or nasal schedule; the loading-and-maintenance routines online come from community convention.
How is this different from Melanotan-2?
Different molecules with different careers. Melanotan-1 is a linear, relatively MC1-selective analog that became an approved EPP drug. Melanotan-2 is a cyclic analog that hits more melanocortin receptors, which is why its discussion sprawls into libido and appetite, and it never became an approved product at all.
Reported practice
Commonly reported protocol
Community tanning protocols. Community-reported patterns, not verified by controlled human trials and not a use recommendation. Full use-pattern detail
Evidence
Evidence snapshot
Scenesse is the regulated afamelanotide product with FDA approval and randomized EPP evidence for increasing pain-free light exposure in adults with phototoxic reactions.
FDA workshop material places afamelanotide in the Melanotan I and Scenesse naming context for EPP. That explains the alias, while every Melanotan-1 spray, vial, or nasal product still has to match Scenesse on implant delivery, exposure, release profile, storage, oversight, and dosing before Scenesse findings are relevant.
Pigmentation biology explains why tanning claims follow the name, but the cited sources are about EPP photoprotection and unregulated-product risk, not a cosmetic tanning regimen.
Review literature on unregulated alpha-MSH analogues describes melanotan I and II use, quality concerns, and reported cutaneous complications. That is a reason to treat unregulated products as a separate risk category.
A 55-person randomized trial compared NB-UVB alone with NB-UVB plus four monthly 16 mg afamelanotide implants. Combination treatment produced earlier and greater repigmentation, with the strongest difference in skin phototypes IV to VI.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Anecdotal evidence | Verdict |
|---|---|---|---|---|
| Melanotan-1 is the same as afamelanotide. | The naming relationship is worth explaining: FDA workshop material connects afamelanotide with Melanotan I and Scenesse in the EPP therapeutic context. | The sequence and pharmacology fit the alpha-MSH analog / MC1 receptor biology that underpins afamelanotide. | Peptide-market and tanning discussions often use Melanotan-1 as the search term even when the approved-product evidence is for Scenesse. | The alias is real; product equivalence is not. The name can point toward afamelanotide, but it does not make a non-approved Melanotan-1 product equivalent to Scenesse. |
| Melanotan-1 improves sun tolerance or photoprotection. | Strongest when stated narrowly: Scenesse is approved to increase pain-free light exposure in adults with EPP and a history of phototoxic reactions, with randomized EPP evidence behind that use. | MC1 receptor activation and increased eumelanin production make the EPP photoprotection question biologically coherent. | Online use tends to flatten this into ordinary sun tolerance, holiday tanning, or burn-resistance language, which goes beyond the studied EPP population. | Valid for regulated Scenesse use in EPP. It is not general photoprotection or a sunscreen substitute. |
| Melanotan-1 is a safer tanning peptide than Melanotan-2. | No cosmetic tanning indication is available for Melanotan-1. The sources describe an approved afamelanotide product in EPP and warnings for unregulated melanotan products. | MC1R selectivity may sound cleaner than broader melanocortin activity, but receptor selectivity does not solve product identity, sterility, concentration, or dermatologic monitoring. | Gray-market discussion often compares MT-1 and MT-2 as tanning options, but those comparisons usually skip the difference between an approved implant and unregulated products. | The real distinction is approved Scenesse versus non-approved melanotan-market products; that distinction is not evidence for a safer cosmetic tanning option. |
| Scenesse evidence applies to research vials or compounded Melanotan-1. | The human evidence is attached to a regulated afamelanotide implant, labeled administration, studied EPP populations, and clinical follow-up. | Same or similar peptide identity still leaves finished-product issues open: release controls, implantation behavior, stability, and adverse-event monitoring. | Product pages and personal-use discussions may cite the Scenesse evidence while selling or discussing products that are not Scenesse. | Using the afamelanotide name still leaves formulation, release, stability, and monitoring evidence to be documented. |
| Melanotan-1/afamelanotide has human evidence in vitiligo. | A randomized multicenter trial enrolled 55 adults with nonsegmental vitiligo and skin phototypes III to VI. All received NB-UVB; 28 also received four monthly 16 mg afamelanotide implants after the first month. Repigmentation started sooner and was greater with the combination, especially in phototypes IV to VI. A four-person precursor report described similar repigmentation with the same combination. | MC1 receptor signaling and eumelanin production provide a rationale, but the human studies combined the implant with NB-UVB and do not establish the implant's effect on its own. | Personal reports involving injectable or nasal Melanotan-1 products concern a different finished product from the controlled-release implant used in the trials. | There is a positive human signal for controlled afamelanotide implants added to NB-UVB, but vitiligo is not a current approved indication. The result does not validate libido, wellness, cosmetic tanning, or gray-market-product claims. |
Bottom line
Main takeaway
If you saw Melanotan-1 marketed for tanning, the short version is this: the name belongs to an approved implant for a rare light-sensitivity disease, and the tanning products using the name are not that drug.
Judge each product on its own. Scenesse, Melanotan-1 vials, Melanotan-2, PT-141, and setmelanotide all touch melanocortin biology, but sharing a pathway does not make them the same molecule, the same product, or the same evidence.
Start with the Scenesse label, the FDA approval documents, and the NEJM EPP trial, then the 55-person vitiligo trial for the repigmentation signal. The unregulated-melanotan review literature documents market-product risk, not benefit.
Identity
What it is
Melanotan-1 is a 13-amino-acid synthetic analog of alpha-MSH, the hormone the body already uses to darken skin after UV exposure. Two amino-acid substitutions made it stronger than the natural hormone, which is why the technical name is NDP-alpha-MSH and why the literature calls it superpotent.
That molecule became afamelanotide, the active ingredient in Scenesse: a regulated 16 mg implant approved in 2019 for adults with erythropoietic protoporphyria. In EPP, visible light can trigger severe phototoxic pain, so a drug that adds pain-free hours of daylight is treating the disease, not deepening a tan.
The confusion is commercial, not chemical. Melanotan-1 survives as a marketplace label on vials, sprays, and nasal products that share at most a name and a sequence with the implant: different manufacturing, different release behavior, different oversight, and none of the shared evidence.
It also sits in a crowded family. Melanotan-2 is a different cyclic analog with its own unapproved-market risk profile, and PT-141 (bremelanotide) and setmelanotide are separate approved melanocortin drugs with their own targets, labels, and populations. Family resemblance is not transferable evidence.
How people talk about it online
Tanning forums treat Melanotan-1 as the milder alternative to MT-2: loading-and-maintenance schedules, pre-holiday timing, freckle and mole reports, and endless comparison threads. The Scenesse photoprotection data get quoted into those threads as if a regulated EPP implant had anything to say about a reconstituted vial.
Search results braid EPP, vitiligo, sun tolerance, skin darkening, libido, and vendor listings into one name. Those topics do not share an evidence package; the cited sources here cover EPP care and product-risk warnings, not cosmetic outcomes.
What almost never appears in market discussion is the paperwork that would actually matter: verified identity, concentration, sterility, storage, and whether anyone medically watches the moles and new lesions this drug family can change.
Use context
Routes, doses, and cycle patterns
The documented study and label pattern is Scenesse: a regulated afamelanotide implant used in EPP. Gray-market Melanotan-1 discussion is real search behavior, but the Scenesse label and EPP studies do not answer cosmetic-tanning questions about route, amount, frequency, or duration.
Human studies and product labels
Scenesse labeled EPP regimen
- Purpose
- Increase pain-free light exposure in adults with EPP and phototoxic-reaction history
- Context
- FDA-approved product label
- Route
- Subcutaneous implant administered by a trained healthcare professional
- Amount
- 16 mg afamelanotide implant
- Frequency
- Every 2 months
- Duration
- Labeled treatment context; duration individualized in clinical care
This label pattern is an implant procedure tied to EPP care, not a reconstituted vial, nasal product, or tanning regimen.
Randomized EPP trial exposure
- Purpose
- Pain-free light exposure and quality-of-life outcomes in EPP
- Context
- Randomized controlled human EPP studies
- Route
- Subcutaneous implant
- Amount
- 16 mg afamelanotide implant
- Frequency
- Repeated implant exposure in the trial program
- Duration
- Study-defined treatment periods in EPP trials
The pivotal trials tie afamelanotide to a real human photodermatosis outcome. They do not give a cosmetic tanning, vitiligo, or general sun-tolerance regimen.
Randomized vitiligo combination trial
- Purpose
- Repigmentation of nonsegmental vitiligo
- Context
- Randomized multicenter comparison of combination therapy with NB-UVB alone
- Route
- Subcutaneous controlled-release implant plus NB-UVB phototherapy
- Amount
- 16 mg afamelanotide per implant
- Frequency
- One implant monthly for four months, starting after one month of NB-UVB
- Duration
- Six-month study period with NB-UVB continued in both groups
The study enrolled 55 adults and found earlier, greater repigmentation with the combination, particularly in skin phototypes IV to VI. It studied a controlled implant, not a Melanotan-1 vial or nasal product.
Clinical-practice EPP follow-up
- Purpose
- Real-world EPP outcome and monitoring context
- Context
- Clinical-practice cohort evidence
- Route
- Afamelanotide treatment in clinical EPP care
- Amount
- Product-specific afamelanotide exposure
- Frequency
- Product and care-context dependent
- Duration
- Follow-up in clinical-practice setting
This shows how EPP treatment is followed outside a pivotal trial. It is not evidence for unregulated Melanotan-1 products.
Real-world discussion
Community tanning protocols
- Purpose
- Tanning and photoprotection discussion
- Context
- Forums, vendors, and protocol blogs
- Route
- Subcutaneous injection
- Amount
- Commonly described around 500 mcg to 1 mg per day during a loading phase, then 1 mg once or twice weekly as maintenance.
- Frequency
- Daily while loading, then weekly in most descriptions
- Duration
- Loading commonly described as 2 to 4 weeks, maintenance open-ended
Melanotan-1 is the community name overlap with afamelanotide, the approved implant; the vial products sold under this name are not that drug. Reported as context, not a recommendation.
What varies
- Product identity: Scenesse is a regulated afamelanotide implant; a product labeled Melanotan-1 is not automatically Scenesse.
- Route: the Scenesse route is subcutaneous implantation; injectable or nasal gray-market products do not inherit that label.
- Amount: 16 mg every 2 months is the Scenesse label pattern, not dosing guidance for non-approved products.
- Goal: EPP photoprotection, cosmetic tanning, vitiligo, libido, and general wellness are different claims with different evidence requirements.
Human data
Human evidence
Nearly all the solid human evidence under this name belongs to afamelanotide as Scenesse in EPP: randomized trials, the FDA label, and clinical-practice follow-up all concern pain-free light exposure in that one population. The vitiligo record is separate and genuinely positive: a 55-person randomized trial found faster and greater repigmentation when 16 mg implants were added to NB-UVB, with the clearest advantage in skin phototypes IV to VI. Neither record was produced by, or speaks for, the vials and nasal products sold as Melanotan-1. For those, the literature is a review of unregulated use and its cutaneous complications, which documents risk rather than benefit.
Evidence maturity
Melanotan-1 is the respectable sibling: same tanning idea, and it actually became a drug for a different disease.
Superpotent melanocortin developed from the tanning research lineage.
16 mg implant approved for erythropoietic protoporphyria.
Loading-and-maintenance injection schedules for tanning, unapproved.
Vials sold as melanotan-1 are not the approved implant product.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Scenesse label and approval | Adults with erythropoietic protoporphyria and a history of phototoxic reactions | FDA-approved label and approval-letter context | Regulated Scenesse afamelanotide implant | Scenesse is indicated to increase pain-free light exposure in the labeled adult EPP population. | The label is limited to adult EPP care with a regulated implant. Cosmetic tanning, general sun tolerance, vitiligo, libido, wellness use, and non-approved Melanotan-1 products would need separate product and outcome evidence. | Strong |
| Afamelanotide randomized EPP evidence | People with erythropoietic protoporphyria in controlled human trials | Randomized controlled human evidence | Afamelanotide implant in EPP research | The pivotal evidence evaluated pain-free light exposure and quality-of-life outcomes in EPP. | EPP is a specific photodermatosis, so the results do not carry over to cosmetic tanning, ordinary sun exposure, or unregulated products. | Strong |
| Afamelanotide clinical-practice evidence | People with EPP receiving afamelanotide in clinical practice | Clinical-practice cohort evidence | Afamelanotide in monitored EPP care | Clinical-practice evidence adds real-world EPP outcome and monitoring context. | Observational follow-up does not make non-approved Melanotan-1 products equivalent to the regulated product. | Moderate |
| Afamelanotide plus NB-UVB for vitiligo | 55 adults with nonsegmental vitiligo and skin phototypes III to VI | Randomized multicenter comparison with NB-UVB monotherapy | Four monthly 16 mg controlled-release implants added after one month of NB-UVB | Repigmentation began sooner and was greater with combination treatment, with a more pronounced treatment difference in skin phototypes IV to VI. | The trial tested afamelanotide with phototherapy, not alone. It was small, vitiligo is not a current approved indication, and controlled implants are not evidence for gray-market Melanotan-1 vials or nasal products. | Moderate |
| Unregulated alpha-MSH analogue review | Reports and discussion around unregulated melanotan I and II use | Peer-reviewed review of unregulated use and case-report literature | Non-approved melanotan-market products | The review supports quality and cutaneous-safety concern language around unregulated melanotan products. | Review and case-report material cannot quantify risk for every product, route, amount, or person, and it does not provide a recommended regimen. | Limited |
Cautions
Safety and unknowns
- Scenesse labeling includes hypersensitivity and anaphylaxis risk language; that safety information applies to the regulated implant, not every product using a Melanotan-1 name.
- Skin monitoring matters. Afamelanotide can affect pigmentation, and unregulated melanotan literature raises cutaneous-complication concerns, so moles, freckles, pigment changes, and new or changing lesions are not cosmetic footnotes.
- Pregnancy, pediatric use, and long-term monitoring questions depend on the exact product and population being discussed. EPP labeling does not answer safety questions for gray-market products.
- Non-approved products create uncertainties the EPP trials leave open: identity, concentration, sterility, endotoxin, degradation, storage, shipment conditions, excipients, and whether the delivered product matches the label.
- Tanning and photoprotection claims can encourage more UV exposure. Scenesse labeling does not make Melanotan-1 a sunscreen replacement or skin-cancer-prevention product.
Product quality
A vial label is only a starting point
The biggest quality mistake is treating a name match as a product match. Scenesse evidence describes a regulated 16 mg afamelanotide implant, not any vial, spray, compounded product, or research-market item labeled Melanotan-1.
Unregulated melanotan products still need peptide identity, strength, sterility, contaminant, storage, and labeling checks. A forum report or product listing does not provide that evidence.
Identity
Melanotan-1, afamelanotide, and Scenesse may overlap in naming, but the actual product has to be clear before the EPP data are relevant.
Finished-product controls
Sterility, excipients, implant design, release behavior, and adverse-event monitoring are product-level facts, not generic peptide facts.
Label and route
The Scenesse route is subcutaneous implantation. A vial or nasal product has a different route and quality problem.
Skin monitoring
Pigmentary effects are part of the drug's biology, so skin changes need medical context rather than cosmetic tanning language.
Mechanism
How it is proposed to work
Melanotan-1/afamelanotide mimics alpha-MSH signaling. By activating the MC1 receptor pathway in skin, it can increase eumelanin production, which helps explain why it is studied and used in EPP photoprotection and why tanning claims follow the name.
Eumelanin is the darker pigment associated with part of the skin's response to ultraviolet exposure. Increasing eumelanin can be relevant in EPP, where painful phototoxic reactions make ordinary light exposure a serious disease burden.
Melanocortin-family biology is broader than MC1R. That is why nearby compounds such as Melanotan-2, bremelanotide, and setmelanotide can have very different claim sets involving pigmentation, sexual function, or appetite signaling.
Receptor biology is not product control. A non-approved Melanotan-1 product still needs evidence for identity, sterility, accurate dosing, and clinical comparability to Scenesse.
Melanotan-1 ([Nle4, D-Phe7]-alpha-MSH) is a superpotent linear alpha-MSH analog: the same molecule as approved afamelanotide. It is more MC1R-selective than melanotan-2, which is why its discussion centers on pigmentation rather than the appetite and libido effects.
FAQ
Common questions
Is Melanotan-1 the same as Afamelanotide?
In FDA terminology materials, Melanotan-1 points to afamelanotide / NDP-alpha-MSH. Products sold or discussed as Melanotan-1 are not automatically equivalent to the regulated Scenesse product.
Does Scenesse approval make tanning-market Melanotan-1 products evidence-backed?
No. Scenesse evidence is attached to an approved afamelanotide product for EPP. Unregulated melanotan products have separate identity, quality, labeling, and safety problems.
Why cover Melanotan-1 separately from Afamelanotide?
People search for Melanotan-1 as a peptide-market term. The name can point to afamelanotide, but the approved evidence is for Scenesse in EPP.
Details
Technical details
Sources
References
- 1.
DailyMed. SCENESSE- afamelanotide implant prescribing information 2026.
Accessed 2026-06-09.
Current structured label source for Scenesse indication, MC1 receptor mechanism, warnings, clinical-trial safety summary, and product identity.
- 2.
FDA. Scenesse (afamelanotide) implant NDA approval letter 2019.
Accessed 2026-06-09.
FDA approval letter for Scenesse as an afamelanotide product used to increase pain-free light exposure in adults with EPP and history of phototoxic reactions.
- 3.
PubMed. Afamelanotide for Erythropoietic Protoporphyria 2015.
doi:10.1056/NEJMoa1411481 PMID:26132941 Accessed 2026-06-09.
Pivotal randomized controlled human evidence in erythropoietic protoporphyria evaluating pain-free light exposure and quality-of-life outcomes.
- 4.
PubMed. Association of Afamelanotide With Improved Outcomes in Patients With Erythropoietic Protoporphyria in Clinical Practice 2020.
doi:10.1001/jamadermatol.2020.0352 PMID:32186677 Accessed 2026-06-09.
Clinical-practice cohort evidence in EPP used for real-world outcome context and safety-boundary framing.
- 5.
FDA. Scenesse (afamelanotide) approval letter, NDA 210797 2019.
Accessed 2026-07-18.
FDA approval letter identifying afamelanotide (Scenesse) as an approved implant for erythropoietic protoporphyria; replaces the earlier EPP workshop slide deck (now offline) as the alias and evidence-boundary source.
- 6.
PubMed. Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review 2017.
doi:10.1111/ijd.13585 PMID:28266027 Accessed 2026-06-09.
Review source for unregulated melanotan I and II use, product-quality concerns, and reported cutaneous complications; used as a safety boundary, not as use guidance.
- 7.
Randomized multicenter vitiligo trial. Lim et al., JAMA Dermatology, 2015, afamelanotide plus NB-UVB for vitiligo
Human vitiligo trial design, implant pattern, repigmentation results, and skin-phototype finding
- 8.
Preliminary vitiligo case series. Grimes et al., JAMA Dermatology, 2013, afamelanotide plus NB-UVB for vitiligo
Four-patient precursor report and monthly controlled-implant pattern